These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34421141)

  • 21. Investigating the effects of age, IQ, dosing, and anthropometric measures on the treatment persistence in long-term methylphenidate use.
    Tuncturk M; Ermis C; Buyuktaskin D; Halac E; Sut E; Ozkan O; Gundogan N; Unutmaz G; Ciray RO; Turan S; Pekcanlar AA
    Nord J Psychiatry; 2023 May; 77(4):345-351. PubMed ID: 36001399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
    J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
    [No Abstract]   [Full Text] [Related]  

  • 23. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial.
    Jahangard L; Akbarian S; Haghighi M; Ahmadpanah M; Keshavarzi A; Bajoghli H; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
    Psychiatry Res; 2017 May; 251():182-191. PubMed ID: 28213188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testicular Function After Long-Term Methylphenidate Treatment in Boys with Attention-Deficit/Hyperactivity Disorder.
    Wang LJ; Lee SY; Chou WJ; Lee MJ; Tsai CS; Lee TL; Yang CJ; Yang KC; Chen CK; Shyu YC
    J Child Adolesc Psychopharmacol; 2019 Aug; 29(6):433-438. PubMed ID: 30575416
    [No Abstract]   [Full Text] [Related]  

  • 26. Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis.
    Carucci S; Balia C; Gagliano A; Lampis A; Buitelaar JK; Danckaerts M; Dittmann RW; Garas P; Hollis C; Inglis S; Konrad K; Kovshoff H; Liddle EB; McCarthy S; Nagy P; Panei P; Romaniello R; Usala T; Wong ICK; Banaschewski T; Sonuga-Barke E; Coghill D; Zuddas A;
    Neurosci Biobehav Rev; 2021 Jan; 120():509-525. PubMed ID: 33080250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.
    Retz W; Rösler M; Ose C; Scherag A; Alm B; Philipsen A; Fischer R; Ammer R;
    World J Biol Psychiatry; 2012 Jan; 13(1):48-59. PubMed ID: 21155632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD.
    Zhang H; Du M; Zhuang S
    Neuropediatrics; 2010 Aug; 41(2):55-9. PubMed ID: 20799150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment response.
    Grebla R; Setyawan J; Park C; Richards KM; Nwokeji ED; Pawaskar M; Haim Erder M; Lawson KA
    J Med Econ; 2019 Aug; 22(8):788-797. PubMed ID: 30983465
    [No Abstract]   [Full Text] [Related]  

  • 30. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of Methylphenidate on Pubertal Maturation and Bone Age in ADHD Children and Adolescents: Results from the ADHD Drugs Use Chronic Effects (ADDUCE) Project.
    Carucci S; Zuddas A; Lampis A; Man KKC; Balia C; Buitelaar J; Danckaerts M; Dittmann RW; Donno F; Falissard B; Gagliano A; Garas P; Häge A; Hollis C; Inglis SK; Konrad K; Kovshoff H; Liddle E; McCarthy S; Neubert A; Nagy P; Rosenthal E; Sonuga-Barke EJS; Wong ICK; Banaschewski T; Coghill D
    J Atten Disord; 2024 Mar; 28(5):722-739. PubMed ID: 38366816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):342-349. PubMed ID: 34081560
    [No Abstract]   [Full Text] [Related]  

  • 34. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?
    Spencer TJ; Faraone SV; Biederman J; Lerner M; Cooper KM; Zimmerman B;
    J Am Acad Child Adolesc Psychiatry; 2006 May; 45(5):527-537. PubMed ID: 16670649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship Between Aggravation of Seizures and Methylphenidate Treatment in Subjects with Attention-Deficit/Hyperactivity Disorder and Epilepsy.
    Park J; Choi HW; Yum MS; Ko TS; Shon SH; Kim HW
    J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):537-546. PubMed ID: 30089215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
    Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
    Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder.
    Greenhill L; Beyer DH; Finkleson J; Shaffer D; Biederman J; Conners CK; Gillberg C; Huss M; Jensen P; Kennedy JL; Klein R; Rapoport J; Sagvolden T; Spencer T; Swanson JM; Volkow N
    J Atten Disord; 2002; 6 Suppl 1():S89-100. PubMed ID: 12685523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADHD and growth: anthropometric changes in medicated and non-medicated ADHD boys.
    Ptacek R; Kuzelova H; Paclt I; Zukov I; Fischer S
    Med Sci Monit; 2009 Dec; 15(12):CR595-9. PubMed ID: 19946228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.